ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / NNVC / dividends
IBO (30) GRDX (39) ALDX (39) BYSI (37) ⌘ Pro Terminal β†’

NanoViricides Inc. (NNVC) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.35 +1.50% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.35

NanoViricides Inc. (NNVC) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $34.5M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NNVC Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is NNVC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, NanoViricides Inc. (NYSE: NNVC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.35 (+1.50% 1D, market cap $34.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NNVC ranks #542 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does NNVC compare to IBO and GRDX in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NNVC carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, IBO (Impact BioMedical Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -27.5%, cap $34.3M) and GRDX (GridAI Technologies Corp.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -20.0%, cap $34.2M). Among the 5-stock peer group, NNVC leads on earnings multiple (N/A) while GRDX leads on capital efficiency (-20.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NNVC?
β–Ό

Per NNVC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001379006), NanoViricides Inc. generated $26.9M in revenue (+12.6% YoY), -$9.5M in net income, and -$8.5M in free cash flow against $12.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.35 (+0.08%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 6/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (37/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510037
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D
Cash (6)Whales (8)SEC (10)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.6% Base Target
$2 Bull$1 Base$1 Bear
πŸ“¬ FREE NNVC RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for NNVC)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
πŸ” WHY NNVC SCORES 37/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–² #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)

FRED Regime Γ— Technicals: 36% of 52W Range β€’ RSI-14 at 48.5 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
29
Grade E$1.31+15.3% Next Q
Q2 (-2Q)
32
Grade E$1.51-4% Next Q
Q3 (-1Q)
34
Grade E$1.45-6.9% Next Q
Current
37
Grade D-$1.35-8.1% Hist 90D Ξ±
Trajectory: E (29) β†’ D- (37)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a NNVC Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While NNVC currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.32) and Max Pain ($1.42) forces dealer call-delta covering toward $2.34.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NNVCβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œNNVC Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $17,081

Est. Year-10 Shareholder Yield: $102/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NNVC)

  • βœ“Walkthrough of NNVC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
NNVC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.53%β–Ό DESCENDING CHANNEL
2026-11-04O $1.33H $1.35L $1.33C $1.35VOL 77.7K
RES: $1.73SUP: $0.88SMA50: $1.32SMA200: $1.29
$2.00$1.73$1.46$1.19$0.92RES $1.73SUP $0.88$1.352026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NNVC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ NNVC Butterfly Map β†’ + Track NNVC β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +12.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NNVC today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for NNVC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NNVC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NNVC)

Health Care Rank #542 of 1015 βš”οΈ IBO vs NNVC Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (NNVC vs. IBO, GRDX, ALDX, BYSI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, NanoViricides Inc. (NNVC) ranks #542 by composite RQD confidence (37/100, grade D-) and #784 by equity capitalization ($34.5M). Within this direct 5-issuer industry benchmark cohort, NNVC leads on earnings valuation at N/A trailing P/E, while GRDX leads on capital efficiency and profitability with -20.0% ROIC and -30.0% gross margin. GRDX currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with NNVC at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NNVC ACTIVE
NanoViricides Inc.
D- 37/100 β€” β€” -35.0% +1.50% $34.5M Benchmark Subject
IBO
Impact BioMedical Inc.
E 30/100 β€” -30.0% -27.5% +5.53% $34.3M /ibo-vs-nnvc β†’
GRDX
GridAI Technologies Corp.
D- 39/100 β€” -30.0% -20.0% -3.43% $34.2M /grdx-vs-nnvc β†’
ALDX
Aldeyra Therapeutics Inc.
D- 39/100 β€” β€” -35.0% +4.09% $35.2M /aldx-vs-nnvc β†’
BYSI
BeyondSpring Inc.
D- 37/100 β€” β€” -35.0% +25.18% $33.1M /bysi-vs-nnvc β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-06-30 β€’ CIK 0001379006 β†—

In its most recent audited fiscal period (FY2025, filed 2025-06-30), NanoViricides Inc. (NNVC) reported GAAP revenue of $26.9M (+12.6% vs. FY2024 revenue of $23.8M , and +7.2% cumulative change since FY2023) , GAAP net income of -$9.5M, operating cash flow of -$8.5M, and free cash flow of -$8.5M (-31.9% YoY). On the balance sheet, NNVC closed FY2025 with $12.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-06-30 $26.9M -$9.5M -$8.5M -$8.5M $12.3M β€”
FY2024 (FY) 2024-06-30 $23.8M -$8.3M -$6.3M -$6.5M $11.6M β€”
FY2023 (FY) 2023-06-30 $25.0M -$8.6M -$5.7M -$5.7M β€” β€”

3. NNVC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NNVC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, NanoViricides Inc. (NYSE: NNVC) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.35 (+1.50% 1D, market cap $34.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, NNVC ranks #542 in composite RQD confidence.

How does NNVC compare to IBO and GRDX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NNVC carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, IBO (Impact BioMedical Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -27.5%, cap $34.3M) and GRDX (GridAI Technologies Corp.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -20.0%, cap $34.2M). Among the 5-stock peer group, NNVC leads on earnings multiple (N/A) while GRDX leads on capital efficiency (-20.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NNVC?

Per NNVC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001379006), NanoViricides Inc. generated $26.9M in revenue (+12.6% YoY), -$9.5M in net income, and -$8.5M in free cash flow against $12.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NNVC trading relative to its 50-day, 200-day, and 52-week technical levels?

NNVC last traded at $1.35 (+1.50% on volume of 77,749 shares), positioning the stock +2.27% above its 50-day simple moving average ($1.32) and +4.65% above its 200-day simple moving average ($1.29). Across its 52-week range of $0.85 to $2.23, NNVC sits at the 36.2% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.18 to $1.52).

Direct Sub-Reports: NNVC RQD Cockpit NNVC 12M Forecast NNVC Earnings & Move NNVC Dividends & DRIP NNVC Insiders & 13F NNVC Whale Options NNVC Profit Sankey NNVC News & Why
ROARABLE RATING BRIEF β€’ RQD 37/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

NNVC β€” NanoViricides Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-06-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

NanoViricides Inc. (NNVC) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.35 (+1.50% 1D, market capitalization $34.5M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of -23.37%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. β€” regarding specific products sold, customer base, or revenue model; the financials report β€” revenue in each reported period. The source notes a $0.0B market capitalization in the profile, which conflicts with the $36.5M figure in market data; this should be treated as an unresolved discrepancy.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-06-30), NanoViricides Inc. (NNVC) reported $26.9M in annual revenue (up from $23.8M in FY2024, +12.6% YoY) and -$9.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($25.0M revenue, -$8.6M net income) through FY2025, NNVC scaled operating cash flow to -$8.5M and free cash flow to -$8.5M, backed by $12.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -23.37% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $0.85 – $2.23 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), NNVC carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can NNVC sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $26.9M and free cash flow of -$8.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NNVC's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NNVC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for NanoViricides Inc. (NNVC) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to NNVC Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NNVC Bull vs. Bear Conversation Board β€” What's Your Call at $1.35?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NNVC 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NNVC:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER β€’ Institutional Buy-Side πŸ‚ BULLISH 🎯 Target: $1.74 (+30.8%)
πŸ“Œ Pinned Debate

Recent safety data on NV-387 in juvenile mice and an ongoing Ebola Phase II trial could support a pediatric clinical pathway.

Don't sleep on NNVC's setup in Health Care. Recent safety data on NV-387 in juvenile mice and an ongoing Ebola Phase II trial could support a pediatric clinical pathway.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (37/100) backs up the fundamental quality.

SectorRotator πŸ‚ BULL

@ForensicBear Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $1.08 (-18.8%)
Spot @ $1.33

Negative ROIC of -35%, negative free cash flow yield of -23.37%, and a $2.375M stock offering point to continued cash burn and dilution

Here is the bear case nobody on the bull side wants to address on NNVC: Negative ROIC of -35%, negative free cash flow yield of -23.37%, and a $2.375M stock offering point to continued cash burn and dilution risk.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE